Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection

Ibalizumab: A novel monoclonal antibody for the management of multidrug resistant HIV-1 infection

(2019) Mario V. Beccari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)

(2019) Richard C Prokesch et al.   Open Forum Infectious Diseases

661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)

(2019) Brinda Emu et al.   Open Forum Infectious Diseases

Ibalizumab in Multidrug-Resistant HIV — Accepting Uncertainty

(2018) Virginia Sheikh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy

(2017) Simona A. Iacob et al.   Frontiers in Microbiology

Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

(2017) Brinda Emu et al.   Open Forum Infectious Diseases

Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review

(2015) Taehwan Park et al.   BIODRUGS

HIV-1 entry inhibitors: recent development and clinical use

(2013) Timothy J Henrich et al.   Current Opinion in Virology

Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope

(2012) Craig S. Pace et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

(2011) J. Toma et al.   JOURNAL OF VIROLOGY

Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

(2010) R. Song et al.   JOURNAL OF VIROLOGY

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

(2010) Michael M. Freeman et al.   STRUCTURE

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

(2008) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?

(2008) D. Grover et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY